Hikma Pharmaceuticals PLC said Monday the chief executive of the U.S. business Michael Raya is retiring after 25 years on the job amid organizational changes at the division.
From July 1, the U.S. business will be organized into two entities–U.S. Generics Division and U.S. Injectables Division–both of which will report to the chairman and the chief executive officer of Hikma, the company said.
The company said it is doing do because it wants to “reflect its enhanced U.S. market positioning and to better align with the global Hikma organization.”
By Olga Cotaga
Source: Market Watch
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).